《药理学》教学通用参考书及推荐阅读文献目录

第一篇：《药理学》教学通用参考书及文献目录

《药理学》教学通用参考书及推荐阅读文献目录

一、教学通用参考书

1． Bertram GK 主编.基础与临床药理学(Basic & Clinical Pharmacology).北京: 人民卫生出版社, McGraw-Hill.第1版, 2001年2月.2． Hardman JG, Limbird LE 主编.治疗学的药理学基础(Goodman & Gliman’s the Pharmacological basis of Therapeutics.10th editon).北京: 人民卫生出版社, McGraw-Hill.第1版, 2002年2月.3． Frishman WH, Sonnenblick EH 主编.心血管药物治疗学(Cardiovascular Pharmacotherpeutics).西安: 世界图书出版公司, McGram-Hill Book Co Singapore, 1998年8月第1次重印.4． 药物治疗学(Pharmacotherapy, 4th edition).北京: 科学出版社, McGram-Hill.英文影印第1版, 2000年9月.5． Topol S 主编.心血管病学(Teabook of Cardiovascular Medicine, 2nd edition).济南: 山东科学技术出版社.第1版, 2003年5月.6． Nestler EJ, Hyman SE, Malenka RC 主编.分子神经药理学龄前(Molecular Neuropharmacology).北京: 人民卫生出版社, McGram-Hill.英文影印第1版, 2001年11月.7． Mycek MJ, Harvey RA, Champe PC 主编.图解药理学散(Lippincott’s lllustrated Reviews: Pharmacology, 2nd edition).北京: 中国协和医科大学出版社, Lippincott Williams & Wilkins.英文影印第1版, 2002年1月.8． 杨藻宸主编.医用药理学.北京: 人民卫出版社.第3版, 1994年6月.9． 杨宝峰主编.药理学.北京: 人民卫出版社.第6版, 2003年8月.10.苏定冯主编.心血管药理学.北京: 科学出版社.第1版, 2001年10月.11.杨藻宸主编.药理学和药物治疗学.北京: 人民卫出版社.第1版, 2000年8月.12.周宏灏主编.分子药理学.哈尔滨: 黑龙江科学技术出版社.第1版, 1999年5月.13.李家泰主编.临床药理学.北京: 人民卫生出版社.第2版, 1997年.14.陈修主编.心血管药理学.北京: 人民卫生出版社.第3版, 2002年.二、推荐阅读文献

第二章 药物代谢动力学

1.Shargel L and Yu A.B.C: Applied Biopharmaceutics and Pharmacokinetics, 3rd ed, East Norwalk, Appleton & Lange, 1993.2.Wilkinson GR.Pharmacokinetics: The Dynamics of Drug Absortion, Distribution, and Elimination.In: Hardman JG and Limbaird LE.Ed.The Pharamcological Basis of Therapeutics.New York.McGraw-Hill.2001，3-30.第三章 药物效应动力学

1.Kenakin TP, Bond RA, Bonner TI.Definition of pharmacological receptors.Pharmacol Rev.1992;44:351-62.2.Stephenson RP.A modification of receptor theory.Br J Pharmacol.1956;379:393 第四章 影响药物效应的因素

1.Moyle G.Double “d” drug danger.AIDS Read.2003;13:15-16, 23-24.2.Rogers JF, Nafziger AN, Bertino JS Jr.Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.Am J Med.2002；15;113:746-750.3.Weinshilboum R.Inheritance and drug response.N Eng J Med.2003 Feb 6;348（6）: 529-537.4.Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ.Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites.N Eng J Med.1989;320:565-570.第五章 传出神经系统药理学概述

1.Jordan D.The autonomic nervous system and behaviour.Acta Neurol(Napoli).1991;13: 539-548.2.Yates BJ, Stocker SD.Integration of somatic and visceral inputs by the brainstem: functional considerations.Exp Brain Res.1998;119:269-275.第六章 胆碱受体激动药和胆碱受体阻断药

1.Pitschner HF, Schlepper M, Schulte B, Volz C, Palm D, Wellstein A.Eelective antagonists reveal different functions of M cholinoceptor subtypes in humans.Trends Pharmacol Sci.1989;Suppl:92-196.2.Takayanagi I, Koike K, Satoh M, Okayasu A.Drug receptor mechanisms in smooth muscle: beta-chloroethylamine-sensitive and-resistant receptor mechanisms.Jpn J Pharmacol.1997;73:1-22.3.Takayanagi I, Koike K, Satoh M.Transition of drug receptor mechanisms.J Smooth Muscle Res.1992;28:35-54.第七章 抗胆碱酯酶药和胆碱酯酶复活药

1.Jokanovic M, Maksimovic M.Abnormal cholinesterase activity: understanding and interpretation.Eur J Clin Chem Clin Biochem.1997;35:11-16.2.Sidell FR.Clinical effects of organophosphorus cholinesterase inhibitors.J Appl Toxicol.1994;14:111-113.第八章 肾上腺素受体激动药

1.Arch JR.beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.Eur J Pharmacol.2002;12;440:99-107.2.Civantos Calzada B, Aleixandre de Artinano A.Alpha-adrenoceptor subtypes.Pharmacol Res.2001;44:195-208.3.Waldeck B.Beta-adrenoceptor agonists and asthma--100 years of development.Eur J Pharmacol.2002;7;445:1-12.第九章 肾上腺素受体阻断药

1.Haeusler G.Pharmacology of beta-blockers: classical aspects and recent developments.J Cardiovasc Pharmacol.1990;16 Suppl 5:S1-S9.2.Wallukat G.The beta-adrenergic receptors.Herz.2002;27:683-690.第十章 局部麻醉药

1.Grant SA.The Holy Grail: long-acting local anaesthetics and liposomes.Best Pract Res Clin Anaesthesiol.2002;16:345-352.2.Leri F, Bruneau J, Stewart J.Understanding polydrug use: review of heroin and cocaine co-use.Addiction.2003;98:7-22.3.Meechan JG.Supplementary routes to local anaesthesia.Int Endod J.2002;35:885-896.第十一章 全身麻醉药

1.Rogers JF, Nafziger AN, Bertino JS Jr.Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.Am J Med.2002;15:746-750.2.Tassonyi E, Charpantier E, Muller D, Dumont L, Bertrand D.The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia.Brain Res Bull.2002;57:133-150.3.Zuurmond WW, Meert TF, Noorduin H.Partial versus full agonists for opioid-mediated analgesia-focus on fentanyl and buprenorphine.Acta Anaesthesiol Belg.2002;53:193-201.第十二章 镇静催眠药

1.Casellas P, Galiegue S, Basile AS.Peripheral benzodiazepine receptors and mitochondrial function.Neurochem Int.2002;40:475-486.2.Mason PE, Kerns WP 2nd.Gamma hydroxybutyric acid(GHB)intoxication.Acad Emerg Med.2002;9:730-739.3.Stahl SM.Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes.J Clin Psychiatry.2002;63:179-180.第十三章 抗精神失常药

1.Crider AM, Scheideler MA.Recent advances in the development of dopamine D（3）receptor agonists and antagonists.Mini Rev Med Chem.2001;1:89-99.2.Frazer A, Benmansour S.Delayed pharmacological effects of antidepressants.Mol Psychiatry.2002;7 Suppl 1:S23-S28.3.Jones HM, Pilowsky LS.Dopamine and antipsychotic drug action revisited.Br J Psychiatry.2002;181:271-275.4.Sawa A, Snyder SH.Schizophrenia: diverse approaches to a complex disease.Science.2002;296:692-695.5.Slassi A.Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications.Curr Top Med Chem.2002;2:559-574.6.Tarsy D, Baldessarini RJ, Tarazi FI.Effects of newer antipsychotics on extrapyramidal function.CNS Drugs.2002;16:23-45.第十四章 抗癫痫药

1.Loscher W.Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.CNS Drugs.2002;16:669-694.2.Pitkanen A.Drug-mediated neuroprotection and antiepileptogenesis: animal data.Neurology.2002;12;59:S27-S33.第十五章 治疗帕金森病及其他运动障碍的药物

1.Factor SA, Friedman JH.The emerging role of clozapine in the treatment of movement disorders.Mov Disord.1997;12:483-496.2.Jankovic J.Complications and limitations of drug therapy for Parkinson's disease.Neurology.2000;55(12 Suppl 6):S2-S6.3.Stern MB.Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview.Neurology.1997;49(1 Suppl 1):S2-S9.4.Tintner and Jackovic.Treatment option for Parkinson’s disease.Current Opinion in Neurology.2002;15:467-476.第十六章 中枢神经系统兴奋药

1.Donovan JL, DeVane CL.A primer on caffeine pharmacology and its drug interactions in clinical psychopharmacology.Psychopharmacol Bull.2001 Summer;35:30-48.2.Frank GC.The power of the perk.Understanding the health effects of caffeine.Adv Nurse Pract.2002;10:43-47.第十七章 解热镇痛抗炎药

1.Aspirin.New uses for an old standby.Mayo Clin Health Lett.2002;20:7.2.Kawai S.Recent development of selective cyclooxygenase-2 inhibitors.Nippon Rinsho.2002;60:2370-2377.3.Pham T.Comparative efficacy of antalgesics and noN-steroidal anti-inflammatory drugs.Presse Med.2002;7;31:4S3-S6.4.Richard Polisson.Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection.Am J Med.1996;2;100: 31-36.第十八章 镇痛药

1.Andersen G, Christrup L, Sjogren P.Relationships among morphine metabolism, pain and side effects during long-term treatment: an update.J Pain Symptom Manage.2003;25: 74-91.2.Przewlocki R, Przewlocka B.Opiods in chronic pain.Eur J Pharmacol.2001;429:79-91.3.Rogers JF, Nafziger AN, Bertino JS Jr.Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.Am J Med.2002;15;113:746-750.第十九章 钙通道阻滞药

1.Arekh AB & Penner R.Store Depletion and Calcium Influx.Pharmacology Review.1997;77:901.2.Gibson A, McFadzean I, Wallace P, et al.Capacitative Ca2+ entry and the regulation of smooth muscle tone.TIPS.1998;19:266.3.Jackson WF.Ion Channels and Vascular Tone.Hypertension.2000;35:173.4.Zhu X & Birnbaumer L.Calcium Channels Formed by Mammalian Trp Homologues.NIPS.1998;13:211.第二十章 抗心肌缺血药

1.Deedwania PC, Carbajal EV.Role of beta blockade in the treatment of myocardial ischemia.Am J Cardiol.1997;80 suppl 2:S23-S28.2.Kubler W.Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants.Z Kardiol.2002;91 Suppl 2:40-48.3.Strashnyi VV, Lysenko AF.Evolution of the market of calcium dihydropyridinic antagonists and their use in the treatment of chronic forms of ischemic heart disease.Lik Sprava.2002;16-20.4.Walenga JM, Fareed J.Current status on new anticoagulant and antithrombotic drugs and devices.Curr Opin Pulm Med.1997;3:291-302.第二十一章 抗高血压药

1.Fisher ND, Hollenberg NK.Is there a future for renin inhibitors? Expert Opin Investig Drugs.2001;10:417-426.2.Guidelines Subcommittee: 1999 World Health OrganizatioN-International Society of hypertinsion guidelines for the management of hypertension.J Hypertens.1999;17: 151-183.3.Hollenberg NK, Sever PS.The past, present and future of hypertension management: a potential role for AT⑴-receptor antagonists.J Renin Angiotensin Aldosterone Syst.2000;1:5-10.4.Oluwole BO, Du W, Mills I, Sumpio BE.Gene regulation by mechanical forces.Endothelium.1997;5:85-93.第二十二章 治疗慢性心功能不全的药物

1.Haas S.Future potential indications for an oral thrombin inhibitor.Hamostaseologie.2002;22:36-43.2.Hermann DD.Beta-adrenergic blockade 2002: a pharmacologic odyssey in chronic heart failure.Congest Heart Fail.2002;8:262-9;283.3.Kohno M, Matsuzaki M.Drugs for the heart failure.Nippon Rinsho.1994;52 Suppl(Pt 1):1072-1079.第二十三章 抗心律失常药

1.Brembilla-Perrot B.Antiarrhythmic drugs in atrial fibrillation.Rev Prat.2002;15;52: 1317-1323.2.The search for novel antiarrhythmic strategies.Sicilian Gambit.Jpn Circ J.1998;62: 633-648.第二十四章 调血脂药和抗动脉粥样硬化药

1.Boumendil EF.Descriptive study of lipid-modulating drug use in a French professional population.J Clin Epidemiol.1994;47:1163-1171.2.Lau BH.Suppression of LDL oxidation by garlic.J Nutr.2001;131:985S-988S.3.Malkonen M, Muona M, Manninen V.Studies on hypoxic dyslipidaemia.Effect of lipid modulating drugs.Acta Med Scand Suppl.1982;668:130-135.4.Miyazaki A, Horiuchi S.Development of new antiatherosclerotic agents--ACAT inhibitors and CETP inhibitors Nippon Rinsho.1999;57:2842-2847.第二十五章 利尿药和脱水药

1.Ambrosioni E, Bacchelli S.Delayed delivery diuretics: from pharmacology to clinical use.ardiologia.1999;44 Suppl 1:533-536.2.Paul S.Balancing diuretic therapy in heart failure: loop diuretics, thiazides, and aldosterone antagonists.Congest Heart Fail.2002;8:307-312.3.Ruzicka M, Leenen FH.Combination therapy as first-line treatment of arterial hypertension.Can J Cardiol.2002;18:1317-27.第二十六章 消化系统药

1.Plosker GL, Lamb HM.Diclofenac/Misoprostol.Pharmacoeconomic Implications of Therapy.Pharmacoeconomics.1999;16:85-98.2.Welage LS, Berardi RR.Evaluation of Omeprazole, Lansoprazole, Pantoprazole, and Rabeprazole in the Treatment of Acid-related Disease.J Am Pharm Assoc.2000;40:52-62.第二十七章 呼吸系统药

1.Campbell LM.From Adrenaline to Formoterol: Advances in Beta-agonist Therapy in the Treatment of Asthma.Int J Clin Pract.2002;56:783-790.2.Karlsson JA, Fuller RW.Pharmacological Regulation of the Cough Reflex—from Experimental Models to Antitussive Effects in Man.Pulm Pharmacol Ther.1999;12: 215-228.第二十八章 子宫平滑肌药

1.de Groot AN, van Dongon PW, Vree TB, Hehster YA, van Roosmalen J.Ergot alkaloids.Current status and review of clinical pharmacology and theraputic use compared with other oxytocics in obstetrics and gynaecology.Drugs.1998;56:523-535.2.den Hertog CE, de Groot AN, van Dongen PW.History and Use of Oxytocics.Eur J Obstet Gynecol Reprod Biol.2001;94:8-12.第二十九章 肾上腺皮质激素类药物

1.Belvisi MG, Brown TJ, Wicks S, Foster ML.New Glucocorticosteroids with an improved therapeutic ratio? Pulm Pharmacol Ther.2001;14:221-227.2.Struthers AD.Aldosterone: cardiovascular assault.Am Heart J.2002;144:S2-S7.3.Szefler SJ.Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid.J Allergy Clin Immunol.1999;104:175-183.第三十章 甲状腺激素和抗甲状腺药

1.Cavalieri RR.Iodine metabolism and thyroid physiology: current concepts.Thyroid.1997;7: 177-181.2.Cooper DS.Antithyroid drugs for the treatment of hyperthyroidism caused by Graves disease.Endocrinol Metab Clin North Am 1998;27:225-224.3.Eng PH, Cardona GR, Fang SL, et al.Escape from the acute Wolff-Chaikoff effect is assocoiated with a decrease in thyroid sodium/iodide sympoter messenger ribonucleic acid and protein.Endocrinology 1999;140:3404-3410.4.Eskandari S, Loo DD, Dai G, et al.Thyroid Na+/I-sympoter, mechanism, stoichiometry, and specificity.J Biol Chem 1997;272:27230-27238.第三十一章 胰岛素及口服降血糖药

1.Gin H, Rigalleau V.Oral anti diabetic polychemotherapy in type 2 diabetes mellitus.Diabetes Metab.2002;28:350-353.2.Horton ES, Clinkingbeard C, Gatlin M, et al.Nateglinide alone and in combination with metformin improves glycemia control by reducing mealtime glucose levels in type 2 diabetes.Diabetes Care.2000;23:1660-1665.3.UK Prospective Diabetes Study Group.Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes(UKPDS 3).Lancet.1998a;352:837-853.第三十二章 性激素类与避孕药物

1.Genazzani AR, Bernardi F.Estrogen effects on neuroendocrine function: the new challenge of pulsed therapy.Climacteric.2002;5 Suppl 2:50-56.2.Pitkin J.Compliance with estrogen replacement therapy: current issues.Climacteric.2002;5 Suppl 2:12-19.第三十三章 组胺与抗组胺药

1.Simons FE, Simons KJ.Clinical pharmacology of H1-antihistamines.Clin Allergy Immunol.2002;17:141-178.2.Winbery SL, Lieberman PL.Histamine and antihistamine in anaphylaxis.Clin Allergy Immunol.2002;17:287-317.第三十四章 5-羟色胺和5-羟色胺受体阻断药

1.Hoyer D, Hannon JP, Martin GR.Molecular, pharmacological and functional diversity of 5-HT receptors.Pharmacol Biochem Behav.2002;71:533-554.2.Jones BJ, Blackburn TP.The medical benefit of 5-HT research.Pharmacol Biochem Behav.2002;71:555-568.第三十五章 抗贫血药

1.Burns DL, Mascioli EA, Bistrian BR.Parenteral iron dextran therapy: a review.Nutrition.1995;11:163-168.2.Kapur D, Agarwal KN, Agarwal DK.Nutritional anemia and its control.Indian J Pediatr.2002;69:607-616.3.Macdougall IC.Strategies for iron supplementation: oral versus intravenous.Kidney Int Suppl.1999;69:S61-S66.第三十六章 作用于凝血系统的药物

1.Burns DL, Mascioli EA, Bistrian BR.Parenteral iron dextran therapy: a review.Nutrition.1995;11:163-168.2.Kapur D, Agarwal KN, Agarwal DK.Nutritional anemia and its control.Indian J Pediatr.2002;69:607-616.3.Macdougall IC.Strategies for iron supplementation: oral versus intravenous.Kidney Int Suppl.1999;69:S61-S66.第三十七章 免疫抑制药

1.Jacobsohn DA.Novel theraputics for the treatment of graft-versus-host disease.Expert Opin Investig Drugs.2002;9:1271-1280.2.Jacobsohn DA, Vogelsang GB.Novel Pharmacotheraputic approaches to prevention and treatment of GVHD.Drugs.2002;62: 879-889.第三十八章 免疫兴奋药

1.Mocellin S, Rossi CR, Lise M, Marincola FM.Adjuvant immunotherapy for solide tumors: from promise to clinical application.Cancer Immunol Immunother.2002;51:583-595.2.Rhodes J.Discovery of immunopotentiatory drugs: current and future strategies.Clin Exp Immunol.2002;130:363-369.第三十九章 抗菌药物概论

1.Bassetti M, Melica G, Cenderello G, Rosso R, Di Biagio A, Bassetti D.Gram-positive bacterial resistance.A challenge for the next millennium.Panminerva Med.2002;44: 179-184.2.Coates A, Hu Y, Bax R, Page C.The future challenges facing the development of new antimicrobial drugs.Nat Rev Drug Discov.2002;1:895-910.3.Labro MT.Antibiotics as anti-inflammatory agents.Curr Opin Investig Drugs.2002;3: 61-68.4.Stewart PS, Costerton JW.Antibiotic resistance of bacteria in biofilms.Lancet.2001;358: 135-138.第四十章 ?-内酰胺类抗生素

1.Mascaretti OA, Danelon GO, Laborde M, Mata EG, Setti EL.Recent advances in the chemistry of beta-lactam compounds as selected active-site serine beta-lactamase inhibitors.Curr Pharm Des.1999;5:939-953.2.Massova I, Mobashery S.Structural and mechanistic aspects of evolution of beta-lactamases and penicillin-binding proteins.Curr Pharm Des.1999;5:929-937.3.Page MI.The reactivity of beta-lactams, the mechanism of catalysis and the inhibition of beta-lactamases.Curr Pharm Des.1999;5:895-913.第四十一章 氨基苷类抗生素

1.Ambrose PG, Owens RC Jr, Garvey MJ, Jones RN.Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime.J Antimicrob Chemother.2002;49:445-453.2.Bolzan AD, Bianchi MS.Genotoxicity of streptozotocin.Mutat Res.2002;512:121-134.3.Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW.Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.Chest.2002;122:219-226.第四十二章 大环内酯类、林可霉素类及多肽类抗生素

1.Paganini H, Marin M.Pharmacokinetic characteristics and antimicrobial spectrum of teicoplanin.Medicina(B Aires).2002;62 Suppl 2:52-55.2.Smilack JD, Wilson WR, Cockerill FR 3rd.Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole.Mayo Clin Proc.1991;66:1270-1280.3.Trefzer A, Salas JA, Bechthold A.Genes and enzymes involved in deoxysugarbiosynthesis in bacteria.Nat Prod Rep.1999;16: 283-299.第四十三章 四环素类及氯霉素类抗生素

1.Leviton I.Inhibitors of protein synthesis.Cancer Invest.1999;17:87-92.2.Watanabe N, Kasahara A, Nakada K, Hayashi J.Mutagens inducing mutations in mammalian mitochondrial DNA.Nippon Rinsho.2002;60:35-38.第四十四章 人工合成抗菌药

1.Hooper DC.Mechanism of action and resistance of older and newer fluroquinolones.Clin Infec Dis.2000;31:S24-S28.2.Labeling requirements for systemic antibacterial drug products intended for human use.Final rule.Fed Regist.2003;68:6062-6081.3.Norrby SR.Side-effects of quinolones: comparisons between quinolones and other antibiotics.Eur J Clin Microbiol Infect Dis.1991;10:378-383.第四十五章 抗结核病药及抗麻风病药

1.Abe C.Multidrug-resistant tuberculosis.Drug susceptibility testing and its standardization.Kekkaku.1998;73:649-655.2.Talwar GP.An immunotherapeutic vaccine for multibacillary leprosy.Int Rev Immunol.1999;18:229-249.3.Volmink J, Garner P.Interventions for promoting adherence to tuberculosis management.Cochrane Database Syst Rev.2000;2:CD000010.4.Wada M.The adverse reactions of anti-tuberculosis drugs and its management.Nippon Rinsho.1998;56:3091-3095.第四十六章 抗真菌药和抗病毒药

1.de Clercq E.Highlights in the development of new antiviral agents.Mini Rev Med Chem.2002;2:163-175.2.Fishman JA.Summary: future directions in antifungal therapy.Transpl Infect Dis.2002;4 Suppl 3:67-68.3.Rebora A.Antiviral drugs: unapproved uses, dosages, or indications.Clin Dermatol.2002;20:474-480.第四十七章 抗寄生虫药

1.Dominguez JN.Chemotherapeutic Agents Agonist Malaria: What Next After Chloroquine? Curr Top Med Chem.2002;2:1173-1185.2.Ridley RG.Medical Need, Scientific Opportunity and the Drive for Antimalarial Drugs.Nature.2002;7;415:686-693.3.Webbe G.Community-wide Treatment of Schistosomiasis with Praziquantel.Trop Doct.1999;29:172-176.第四十八章 抗恶性肿瘤药物

1.Mormont MC, Levi F.Cancer chronotherapy: priciples, applications, and perspectives.Cancer.2003;97: 155-169.2.Schwartsmann G, Ratain MJ, Cragg GM, Wong JE, Saijo N, Parkinson DR, Fujiwara Y, Pazdur R, Nemman DJ, Dagher R, DiLeone L.Anticancer drug discovery and development throughout the world.J Clin Oncol.2002;20: 47-59.

第二篇：小组文献目录

南昌大学社会学系

国外社会学理论（WST）小组作业（小组参考文献）

参考文献

计划参考文献：

1.庞明礼，《新读书无用论与大学生就业压力相关性研究》，《高校教育管理》第7卷第2期,2013年3月

2.祝伟，《大学生就业压力计缘何年年攀》，《经济日报》第003 版，2014 年1 月9 日

3.周荣，《大学生就业难的成因与对策分析》，《合肥师范学院学报》第13卷第5期，2013年9月

4.吕峰，《大学生就业现状调查》，《华章》第2期，2014年

5.林双，《对社会工作专业毕业生就业难问题的研究》，《人资社科》（才智第261页）

6.李延保，《理性认识中国大学教育的改革与发展》，《理性思考》中国高等教育第5期，2010年

7.钱颖一，《论大学本科教育改革》，《清华大学教育研究》第32卷第1期，2011年2月

8.张露，《试析用工荒背景下的大学生就业难问题》，《学校与社会》文章，编号：1674-9324(2013)12一0236一03，2013年

9.王大玮，《试析大学生就业心理问题的综合研究》，《实践·思考》民营科技第1期，2014年

10.黄敬宝，《我国大学生就业政策的演变及评价》，CHINALABOR《论坛》,2013年3月

11.付静，《中国大学生就业现状分析》，《实践•思考》民营科技第3期，2013年

12.王莉，《国内外大学生就业状况比较研究》，《中国科教创新导刊》第32期，2009年

13.北京大学教育经济研究所，《大学生就业调查：2013年大学生就业状况究竟怎样》，2014年01月28日14:23来源：新华网

国外社会学理论小组作业（参考文献）。社会工作121班。第七组：马倩娜、田娇婵、邢顺昌、刘洪俊

第三篇：药理学教学总结

药理学教学总结

------李达

药理学是医学教育中一门重要的必修课,其内容具有系统性不强、知识点零碎、复杂抽象、理论性强、涉及学科面广等特点;再加上开设这门课程时学生还没有接触临床的专业课知识,理论与实际脱节;所以学生普遍反映难学难记且易混淆,是公认的最难学科目之一。本人从事药理学教学工作多年,深受学生好评。现就自己在药理学教学实践中几点心得进行浅述,以与同行共勉。扎实的基础医学知识和丰富的临床经验药理学是一门桥梁性学科,既与生理学、生物化学、病理学等基础课有着广泛的联系,还与内科学、外科学、精神病学密切相关。所以就要求药理学教师既要多翻阅基础医学资料,又要有丰富的临床经验,以有临床工作经验者为最佳。满腔的热情和高昂的激情这是激发学生学习热情的基本条件。如果教师讲课时缺乏激情,如同老和尚念经,学生对药理学也不会有兴趣,更不会取得良好的教学效果。3 灵活多样的课堂教学形式 3.1 归纳总结

归纳总结可以将零碎的知识点串联起来,相对系统化,便于牢固掌握、记忆。本人在实践教学中主要对每个系统进行总结,即将该系统的主要内容罗列,并将重要掌握的知识点和药物列在主要内容之后,这样就使学生从宏观上把握该系统的主要内容和重点。此方法在历届学生教学评价中均得到好评。归纳总结也可以在其他知识层面应用,比如对药物的药理作用、临床用途及不良反应进行总结。3.2 比较法

在药理学教学实践中,运用比较法能系统地理清概念的脉络,便于记忆。不同章节,但有一定共同点的药物,例如： 镇痛药和解热镇痛药,可以从概念,镇痛的部位和性质,临床用途和不良反应等方面横向比较学习。同样可以把解热镇痛药和抗精神病药氯丙嗪的解热机制、特点做一比较。同一系统的药物,例如： 吗啡、甲基吗啡(可待因),和哌替啶,可以根据各药物之间的逻辑关系,结构特性及药理作用等方面纵向比较,由主到次,由浅入深,对比学习记忆。3.3 理论联系实际

《药理学》 不同于 《临床药理学》 ,是以基础理论为主的一门课,教材中基本没有临床病例,是大家公认的枯燥难学的课程。本人曾从事临床工作10余年,在教学实践中经常把个人的临床经历讲给学生,不但大大提高了学生的兴趣,也使学生深入理解理论和实践的相互关系。比如在讲到 “有机磷酸酯类药物中毒”时,本人把在临床工作中抢救经验介绍给学生,使学生对 “有机磷酸酯类药物中毒” 的多发性、抢救要领都有了深刻了解。3.4 贯通式授课法

传统的药理学授课方式是分步骤进行,即按照体内过程→作用机制→药理作用→临床应用→不良反应顺序进行讲解。本人在教学实践中,部分内容打破这种顺序,采用贯通式方法,即把与某一个知识点相关的内容全部讲完,比如在讲到硝酸甘油扩张血管作用时,按照下列顺序讲解：扩张血管,降低血压(药理作用)→治疗高血压(临床应用)→引起低血压(不良反应),这样就是零碎的知识点具有连贯性,学生听起来也比较轻松。当后面有重复时就可以一带而过。3.5 充分利用网络资源

当今是一个信息时代,网络为我们提供了丰富的资源。在教学过程中,要充分。利用网络上的资源为教学服务,比如把吗啡成瘾的实验视频和癫痫不同类型的临床表现视频放给学生看,使学生产生直观的感性认识,活跃课堂气氛,提高学生听课情绪。其他资源比如动画的应用也取得了良好的教学效果。3.6 板书图解法

多媒体在教学过程中已经普及,板书也离我们渐行渐远。其实板书具有多媒体不可取代的优点,板书直观、清晰,便于学生理解和记忆,正所谓尺有所短,寸有所长。教学过程中,适当板书会取得良好效果,比如在总论部分,学生对于 “药物经过5个半衰期基本消除”和 “恒量给药,经过5个半衰期药物达到稳态浓度” 这两句话很难理解,这时如果老师在黑板上给予计算和画图,则显得浅显易通,非常直观。再如抗帕金森病药,学生对于运动神经元的支配和帕金森病的发病机制难以理解,如果利用板书画图,就比较直观,讲解比较轻松,取得很好的教学效果。适当转换课堂教学语言由于药理学涉及相关学科的内容较多,学生对药理学的学习,一是有畏难情绪,二是觉得枯燥无味,所以教师尽可能用通俗简洁、生动趣味的语言替换原本枯燥

乏味的专业术语和逻辑关系,增强学生的情感,驱除疲劳,同时也增进了师生之间的默契和友谊。

总之,教学是一门艺术,教师要多站在学生的角度去考虑如何把课讲得生动有趣,条理清楚。同时,药理学是一门前沿学科,知识更新换代比较快,所以教师要不懈努力,在教学手段和内容方面跟上时代的步伐。

2015年1月11日星期日

李达

第四篇：诗词吟唱曲谱文献目录

诗词吟唱曲谱文献目录

诗词吟唱曲谱文献目录

作者:楚石

2010-08-15 16:54 星期日 晴

诗词曲在古代都可以被歌唱，这是毫无疑义的。但今天还能唱吗？很多人怀有疑问，这就涉及到古诗词曲乐谱的保存和整理现状。据我的调查，古诗词曲乐谱仍有相当的遗存，如果经过抢救和整理，应能满足我们研究之需，加上现代的音乐文学学者根据古调新创作，其数量也足够我们文学教育之用。我们抱着发展的眼光，一面保存整理，一面根据古腔古韵新创，就可以使古诗词继续传唱下去。

现存古诗词乐谱一般有三种情况，一是古谱，二是前人传腔后人记谱，三是今人根据古韵新创曲谱。古谱中最著名的有

1《白石道人歌曲》，宋代姜夔的词曲谱集。共4卷，别集1卷。书中收有祀神曲《 越九歌 》 10首，词调令、慢、近、犯17首，琴曲《古怨》1首。

2《魏氏乐谱》。是逃亡日本的明代乐官所编辑的中国古代歌曲集。明末乐官魏之琰在甲申之变后东渡日本，定居长崎，将祖传中国古代歌曲教授给弟子，后由其四世孙魏浩从200余曲中选辑50余首刊印成书，取名《魏氏乐谱》。该书保存的歌曲，从诗经的《关雎》《伐檀》到汉代的《秋风辞》《长歌行》，风格较为古朴。

3《九宫大成南北词宫谱》。这是一部戏曲音乐曲谱集。乾隆六年和硕庄亲王允禄奉旨编纂，由乐工周祥钰、邹金生、徐兴华、王文禄、朱廷镠、徐应龙等人搜集整理而成。

《九宫大成南北词宫谱》。共82卷，南北曲曲牌2094个，曲谱4466首。内容包括唐五代宋词、金元诸宫调、元代散曲、明朝散曲、南戏、北杂剧、明清崑腔等内容，其中唐宋词曲谱有数百首。

4《碎金词谱》。这是《九宫大成南北词宫谱》的精选本，保存了大量的诗词曲谱资料。

5《纳书楹曲谱》。清代苏州叶堂编著，主要收录昆曲曲谱，但有一些元曲曲牌可供参考歌唱。

6《弦歌雅韵》（原名《琴歌》）。古琴名家王迪女士毕生研究琴歌，她从数十种古琴谱当中选择有曲有辞者近百首，汇编一册，其中大量是诗词作品，比如《关山月》《竹枝词》《渔歌调》。

7《乐府歌诗古乐谱百首》，刘崇德译谱。河北大学出版社2001年版。

这些古代曲谱保存了古代歌曲的原貌，古腔古韵，原汁原味，虽然在译谱过程中难免讹误，但其价值仍然是无可估量的。

现代人因家传师授，从小吟诵古诗词曲，并致力于古诗词吟唱之研究，保留了大量曲谱，这些数量也颇不少。比较重要的有：

1《吟诵曲谱》，秦德祥编。中国文联出版社2002年版。

2《赵元任程曦吟诵遗音录》，秦德祥编。商务印书馆2009年版。

3《古诗词文吟诵研究》，陈少松著。社会科学文献出版社2002年版。

4《陈炳铮吟诵曲选》，陈炳铮著。油印本

5《中国古诗词吟诵曲谱》，茆家培、盘石编，江苏文艺出版社1995年版。

6《古诗文吟诵集粹》，王恩保编。北京语言学院出版社1993年出版。（此书余未购得）

7《诗经吟诵与解说》，魏子云著，台湾巨流图书公司1986年版。

现代学者或音乐家新创作的诗词曲谱也颇不少：

1《中国古典诗词曲谱选释》，傅雪漪著，中国戏剧出版社1996年版。

2《中国古代诗词歌曲集》，江西人民出版社1986年版。

3《中国古典诗词歌曲集》，林光旋编，中国青年出版社1994年版。

4劳在鸣《古典诗词吟唱曲谱》，武汉大学出版社2006年版。

5辛清华《诗词曲谱》，上海音乐出版社2005年版。

6黄慰平《古诗词吟唱曲》，百家出版社1989年版。

7林光旋《中国古典诗词歌曲集》，中国青年出版社1994年版。

8蔡肇祺，《谱李白诗怀李白》台湾中华民国意识科学研究所。（此书余未购得）

9《李白诗词吟诵曲选》，盘石编，安徽文艺出版社2001年版。

10《古韵新唱－－古典诗词吟唱集》，许以正编曲，学林出版社2008年版。

11《古韵新声：潘丽珠吟诵教学》，台湾幼狮出版社2003年版。

12《诗经与楚辞音乐研究》，梁志锵著，上海古籍出版社2010年版。

以上乐谱总计二十余种，曲目难以计数，大致在千首以上。另外还有大量港台吟唱谱有待整理发现。如何从这些古今乐谱中发现既富古韵，又有音乐美的作品，并把这些唱腔传承下去，可以说是古典诗词曲研究者的重要任务之一。

第五篇：内部控制英文文献目录

内部控制英文文献目录

1.内部控制管制对盈余质量的影响：来自德国的证据（March 2008）The effect of internal control regulation on earnings quality: Evidence from Germany 2.内部控制制度如何影响财务报告？（Altamuro，June 24, 2009）How Does Internal Control Regulation Affect Financial Reporting 3.财务报告内部控制缺陷的决定因素（Doyle，May 15, 2006）Determinants of weaknesses in internal control over financial reporting 4.应计质量与财务报告内部控制（Doyle，January 24, 2007）Accruals Quality and Internal Control over Financial Reporting 5.SOX内部控制缺陷对公司风险与权益资本成本的影响（Ashbaugh-Skaife，June 10, 2008）The Effect of SOX Internal Control Deficiencies on Firm Risk and Cost of Equity 6.审计委员会质量、审计师独立性与内部控制缺陷（Zhang）

Audit Committee Quality, Auditor Independence, and Internal Control Weaknesses 7.小企业受益于内部控制缺陷审计师认证吗

Do Small Firms Benefit from Auditor Attestation of Internal Control Effectiveness 8.内部控制缺陷的决定因素（Jahmani）

Determinants of Internal Control Weaknesses In Accelerated Filers 9.操控性应计项目能帮助区分内部控制缺陷和欺诈吗

Do Discretionary Accruals Help Distinguish between Internal Control Weaknesses and Fraud 10.财务报告质量对债务契约的影响：来自内部控制缺陷报告的证据（Costello，September 4, 2010）The impact of financial reporting quality on debt contracting: Evidence from internal control weakness reports 11.重大内部控制缺陷与盈余管理

Material Internal Control Weaknesses and Earnings Management in the Post-SOX Environment 12.家族企业的内部控制（April 2013）Internal Controls in Family-Owned Firms（）13.内部控制质量对企业并购绩效的影响研究

Study on the Impact of the Quality of Internal Control on the Performance of M&A 14.内部控制质量与信用违约互换利差（January 2014）Internal Control Quality and Credit Default Swap Spreads 15.家族企业内部控制：特征和后果

Internal Control in Family Firms: Characteristics and Consequences 16.内部控制报告与会计信息质量：洞察‖遵守或解释的―内部控制制度

Internal control reporting and accounting quality：Insight “comply-or-explain” internal control regime 17.内部控制报告与会计稳健性

Internal Control Reporting and Accounting Conservatism 18.会计信息质量影响产品市场契约吗？来自政府合同授予的证据（March 2014）

Does Accounting Quality Influence Product Market Contracting? Evidence from Government Contract Awards 19.公司特征与财务报告质量：尼日利亚制造业上市公司的证据 20.内部控制情况与专家审计师选择

The Association between Internal Control Situations and Specialist Auditor Choices 21.审计费用反应了控制风险的风险溢价吗（2013-07）Do Audit Fees Reflect Risk Premiums for Control Risk? 22.内部控制质量与审计定价

Internal Control Quality and Audit Pricing under the Sarbanes-Oxley Act 23.内部控制缺陷与权益资本成本：来自萨班斯法案404节披露的证据

Internal Control Weakness and Cost of Equity: Evidence from SOX Section 404 Disclosures 24.内部控制缺陷与信息不确定性

Internal Control Weaknesses and Information Uncertainty 25.重大内部控制缺陷与股票价格崩溃危险：来自404条款披露的证据（May 2013）

Material Weakness in Internal Control and Stock Price Crash Risk: Evidence from SOX Section 404 Disclosure 26.SOX内部控制缺陷对公司风险与权益资本成本的影响

The Effect of SOX Internal Control Deficiencies on Firm Risk and Cost of Equity 27.信用评级、债务成本与内部控制信息披露：SOX302和SOX404法的比较 28.萨班斯-奥克斯利法案对会计信息债务契约价值的影响

The Effect of Sarbanes-Oxley on the Debt Contracting Value of Accounting Information 29.财务报告内部控制的不利意见与审计师解聘/辞职

Adverse Internal Control over Financial Reporting Opinions and Auditor Dismissals/Resignations 30.新管理人员任命与随后的SOX法案404的意见

Appointment of New Executives and Subsequent SOX 404 Opinion

31.萨班斯奥克斯利：有关萨班斯法案404影响的证据 Sarbanes-Oxley: The Evidence Regarding the Impact of Sox 404 32.内部控制有效性自愿披露的经济决定因素及后果：从首次公开发行的证据（March 2013）Economic Determinants and Consequences of Voluntary Disclosure of Internal Control Effectiveness: Evidence from Initial Public Offerings 33.非营利组织中内部控制问题的原因和后果

The Causes and Consequences of Internal Control Problems in Nonprofit Organizations 34.SOX内部控制披露在公司控制权市场中的价值

The Value of SOX Internal Control Disclosures in the Market for Corporate Control 35.内部控制缺陷与销售、一般的及行政费用的非对称性行为

Internal Control Weakness and the Asymmetrical Behavior of Selling, General, and Administrative Costs 36.内部控制缺陷及补救措施披露对投资者感知的盈余质量的影响

The Impact of Disclosures of Internal Control Weaknesses and Remediation on Investor-Perceived Earnings Quality 37.内部控制缺陷与美国上市的中国公司与美国公司的审计师

SOX Internal Control Deficiencies and Auditors of U.S.-Listed Chinese versus U.S.Firms 38.内部控制信息披露与代理成本—来自瑞士的非金融类上市公司的证据（January 2013）Internal Control Disclosure and Agency Costs Evidence from Swiss listed non-financial Companies 39.萨班斯奥克斯利法案与公司投资：来自自然实验的新证据

The Sarbanes-Oxley Act and Corporate Investment: New Evidence from a Natural Experiment 40.国内投资者保护、所有权结构与交叉上市公司遵守SOX要求披露内部控制缺陷

Home Country Investor Protection, Ownership Structure and Cross-Listed Firms’ Compliance with SOX-Mandated Internal Control Deficiency Disclosure 41.审计师对披露重大缺陷相关风险的看法

Auditors’ Perceptions of the Risks Associated with Disclosing Material Weaknesses 42.交叉上市公司提供与美国公司相同质量的披露？来自萨班斯-奥克斯利法案302条款下的内部控制缺陷信息披露的证据

Do cross-listed firms provide the same quality disclosure as U.S.firms? Evidence from the internal control deficiency disclosure under Section 302 of the Sarbanes-Oxley Act 43.内部控制缺陷与并购绩效

Internal Control Weaknesses and Acquisition Performance 44.萨班斯-奥克斯利法案302条款下的内部控制缺陷对审计费用的影响

The Effect of Internal Control Weakness under Section 404 of the Sarbanes-Oxley Act on Audit Fees 45.审计师对财务报告内部控制的评价对审计费用、债务成本及净遵从收益

The Effect of Auditors’ Assessment of Internal Control of over Financial Reporting on Audit Fees, Cost of Debt and Net Compliance Benefit 46.上市公司披露的信息含量与萨班斯-奥克斯利法案

Information Content of Public Firm Disclosures and the Sarbanes-Oxley Act 47.财务错报与股票市场的契约：从增发的证据

Financial Misstatements and Contracting in the Equity Market: Evidence from Seasoned Equity Offerings 48.公司治理质量与SOX 302条款下内部控制报告

Corporate Governance Quality and Internal Control Reporting Under Sox Section 302 49.审计委员会质量、审计师独立性与内部控制缺陷

Audit Committee Quality, Auditor Independence, and Internal Control Weaknesses 50.SOX404条款的影响：成本，盈余质量与股票价格

The Effect of SOX Section 404: Costs, Earnings Quality, and Stock Prices 51.内部控制缺陷与银行贷款契约：来自SOX404条款披露的证据 Internal Control Weakness and Bank Loan Contracting: Evidence from SOX Section 404 Disclosures 52.审计师对财务报告内部控制的决策：分析、综合和研究方向

Auditors’ Internal Control Over Financial Reporting Decisions: Analysis, Synthesis, and Research Directions 53.应计质量与财务报告内部控制（Doyle，The Accounting Review, forthcoming）Accruals Quality and Internal Control over Financial Reporting 54.业绩基础CEO和 CFO 薪酬对内部控制质量的影响

The impact of performance-based CEO and CFO compensation on internal control quality 55.内部控制重大缺陷与CFO 薪酬

Internal Control Material Weaknesses and CFO Compensation 56.财务报告内部控制缺陷的决定因素

Determinants of weaknesses in internal control over financial reporting 57.内部控制与管理指南

Internal Control and Management Guidance 58.2002萨班斯-奥克斯利法案302条款下内部控制缺陷的市场反应以及这些缺陷的特征 Market Reactions to the Disclosure of Internal Control Weaknesses and to the Characteristics of those Weaknesses under Section 302 of the Sarbanes Oxley Act of 2002 59.自愿报告内部风险管理和控制系统的经济激励

Economic Incentives for Voluntary Reporting on Internal Risk Management and Control Systems 60.后萨班斯法案时代审计意见的信息含量

The information content of audit opinions in the post-sox era 61.上市公司披露的信息含量与萨班斯-奥克斯利法案（April, 2010）Information Content of Public Firm Disclosures and the Sarbanes-Oxley Act 62.信息摩擦如何影响公司资产流动性的选择？萨班斯法案404条款的影响

How do Informational Frictions Affect the Firm’s Choice of Asset Liquidity? The Effect of SOX Section 404 63.已审计的信息披露给资本市场参与者带来利益是什么（December 19, 2013）What are the benefits of audited disclosures to equity market participants 64.诉讼风险与审计定价：公众股权的作用（January 7, 2013）Litigation Risk and Audit Pricing: The Role of Public Equity 65.萨班斯-奥克斯利法案对IPO和高收益债券发行人的影响 The Impact of Sarbanes-Oxley on IPOs and High Yield Debt Issuers 66.来自金融危机的公司治理的经验教训

The Corporate Governance Lessons from the Financial Crisis 67.谁对企业欺诈吹口哨

Who Blows the Whistle on Corporate Fraud 68.内部控制缺陷与现金持有价值 Internal Control Weakness and Value of Cash Holdings 69.民族文化和制度环境对内部控制信息披露的影响

The impact of national culture and institutional Environment on internal control disclosures 70.财务报告质量与权益资本成本之间联系的讨论：一些个人的意见（June 6, 2013）

Some Personal Observations on the Debate on the Link between Financial Reporting Quality and the Cost of Equity Capital 71.使用盈利预测同时估计企业层面的权益资本成本和长期增长

Using Earnings Forecasts to Simultaneously Estimate Firm-Specific Cost of Equity and Long-Term Growth

72.高管薪酬差距与权益资本成本

Executive Pay Disparity and the Cost of Equity Capital 73.财务报告质量与公司债券市场（博士论文，Mingzhi Liu, 2011）Financial Reporting Quality and Corporate Bond Markets

References Aboody, D., J.Hughes, and J.Liu.(2005)Earnings quality, insider trading, and cost of capital.Journal of Accounting Research 43: 651–673.Akins, B., J.Ng and R.Verdi(2012)Investor competition over information and the pricing of information asymmetry.The Accounting Review 87(1): 35-58.Ali, A., A.Klein and J.Rosenfeld.(1992)Analysts’ use of information about permanent and transitory earnings components in forecasting annual EPS.The Accounting Review 67: 183-198.Amihud, Y., and H.Mendelson.(1986)Asset pricing and the bid-ask spread.Journal of Financial Economics 17: 223–249.Artiach, T.and P.Clarkson.(2011)Disclosure, conservatism and the cost of equity capital: A review of the foundation literature.Accounting and Finance 51(1): 2-49.Ashbaugh-Skaiffe, H., D.Collins, W.Kinney, Jr., and R.LaFond(2009)The effect of SOX internal control deficiencies on firm risk and cost of equity.Journal of Accounting Research 47(1): 1-43.Armstrong, C., J.Core, D.Taylor and R.Verrecchia(2011)When does information asymmetry affect the cost of capital? Journal of Accounting Research 49(1): 1-40.Balakrishnan, K., R.Vashishtha and R.Verrecchia(2012)Aggregate competition, information asymmetry and cost of capital: Evidence from equity market liberalization.Working paper, University of Pennsylvania.Barron, O., O.Kim, S.Lim and D.Stevens(1998)Using analysts forecasts to measure properties on analysts’ information environment.The Accounting Review 73: 421-433.Barry, C., and S.Brown.(1985)Differential information and security market equilibrium.Journal of Financial and Quantitative Analysis 20: 407–422.Barth, M., W.Beaver, and W.Landsman(2001)The relevance of value-relevance literature for financial accounting standard setting: Another view,‖ Journal of Accounting and Economics(Sept): 77-104.Barth, M., Y.Konchitchki and W.Landsman(2013)Cost of capital and earnings transparency.Journal of Accounting and Economics, forthcoming.Beyer A., D.Cohen, T.Lys and B.Walther(2010)The financial reporting environment: Review of the recent literature.Journal of Accounting and Economics 50: 296-343.Bhattacharya, N., F.Ecker, P.Olsson, and K.Schipper(2012)Direct and mediated association among earnings quality, information asymmetry, and the cost of capital, The Accounting Review 87(2): 449-482.Botosan, C.(1997)Disclosure level and the cost of equity capital.The Accounting Review 72: 323–350.Botosan, C., and M.Plumlee.(2002)A re-examination of disclosure level and the expected cost of equity capital.Journal of Accounting Research 40: 21–40.Botosan, C., M.Plumlee and Y.Xie(2004)The role of information precision in determining the cost of equity capital.Review of Accounting Studies 9(2-3): 233-259.Botosan, C., and M.Plumlee.(2005)Assessing alternative proxies for the expected risk premium.The Accounting Review 80: 21-53.Botosan, C., M.Plumlee and H.Wen.(2011)The relation between expected returns, realized returns, and firm risk characteristics.Contemporary Accounting Research 28(4): 1085-1122.Brown, P.and T.Walter(2012)The CAPM: Theoretical validity, empirical intractability and practical applications.Abacus 1-7.Callahan, C., R.Smith and A.Spencer(2012)An examination of the cost of capital implications of FIN 46.The Accounting Review 87(4): 1105-1134.Chava, S., and A.Purnanandam(2010)Is default risk negatively related to stock returns? Review of Financial Studies 23: 2523-2559.Chen, S., B.Miao and T.Shevlin(2013)A new measure of disclosure quality: The level of disaggregation of accounting data in annual reports.Working paper, The University of Texas at Austin.Christensen, P., L.de la Rosa and G.Feltham(2010)Information and the cost of capital: An ex ante perspective.The Accounting Review 85(3): 817-848.Clarkson, P., J.Guedes and R.Thompson(1996)On the diversifiability, observability, and measurement of estimation risk.Journal of Financial and Quantitative Analysis 31: 69084.Claus, J., and J.Thomas(2001)Equity premia as low as three percent? Evidence from analysts’ earnings forecasts for domestic and international stock markets.The Journal of Finance 56(5): 1629-1666.Clinch G., and B.Lombardi(2011)Information and the cost of capital: the Easley-O’Hara(2004)model with endogeneous information acquisition.Australian Journal of Management 36(5): 5-14.Coles, J., U.Loewenstein, and J.Suay.(1995)On equilibrium pricing under parameter uncertainty.The Journal of Financial and Quantitative Analysis 30: 347–374.Core, J.,(2001)A review of the empirical disclosure literature: Discussion.Journal of Accounting and Economics 31: 441-456.Core, J., W.Guay and R.Verdi,(2008)Is accruals quality a priced risk factor? Journal of Accounting and Economics 46: 2-22.Daniel, K.and S.Titman, 1997, Evidence on the characteristics of cross-sectional variation in common stock returns.Journal of Finance 52, 1-33.Daske, H., L Hail, C.Leuz and R.Verdi(2008)Mandatory IFRS reporting around the world: Early evidence on the economic consequences.Journal of Accounting Research 46: 1085-1142.Daske, H., L Hail, C.Leuz and R.Verdi,(2013)Adopting a label: Heterogeneity in the economic consequences around IAS/IFRS adoptions.Journal of Accounting Research 51(3):495-548.Dechow, P.and I.Dichev.(2002)The quality of accruals and earnings: the role of accrual estimation errors.The Accounting Review 77(Supplement): 35-59.Dechow, P., W.Ge and C.Schrand(2010)Understanding earnings quality: A review of the proxies, their determinants and their consequences.Journal of Accounting and Economics 50: 344-401.Dhaliwal, D., L.Krull and W.Moser(2005)Dividend taxes and implied cost of equity capital.Journal of Accounting Research 43(5): 675-708.Dhaliwal, D., L.Krull and O.Li(2007)Did the 2003 Tax Act reduce the cost of equity capital? Journal of Accounting and Economics 43(1): 121-150.Diamond, D., and R.Verrecchia.(1991)Disclosure, liquidity, and cost of capital.Journal of Finance 46: 1325–59.Dye, R.,(2001)An evaluation of ―essays on disclosure‖ and the disclosure literature in accounting.Journal of Accounting and Economics 32: 181-235.Easley, D., S.Hvidkjaer and M.O’Hara.(2002)Is information risk a determinant of asset returns.Journal of Finance 57: 2185-2221.Easley, D., and M.O’Hara.(2004)Information and the cost of capital.Journal of Finance 59: 1553–1583.Easton, P.(2004)PE ratios, PEG ratios, and estimating the implied expected rate of return on equity capital.The Accounting Review 79(1): 73-96.Easton, P., and S.Monahan.(2005)An evaluation of accounting based measures of expected returns.The Accounting Review 80: 501–538.Easton, P., and S.Monahan.(2010)Evaluating accounting-based measures of expected returns: Easton and Monahan and Botosan and Plumlee redux.Working paper, University of Notre Dame.Ecker, F., J.Francis, I.Kim, P.Olsson, and K.Schipper(2006).A returns-based representation of earnings quality.The Accounting Review 81: 749–780.Fama, E., and J.MacBeth.1973.Risk, return, and equilibrium: Empirical tests.Journal of Political Economy 81: 607–636.Fama, E., and K.French.(1992)The cross-section of expected stock returns.Journal of Finance 47(2): 427-465.Fama, E., and K.French.(1993)Common risk factors in the returns on bonds and stocks.Journal of Financial Economics 33: 3–56.Francis, J., LaFond, R., Olsson, P., and K.Schipper.(2004)Costs of equity and earnings attributes.The Accounting Review 79: 967-1010.Francis, J., LaFond, R., Olsson, P., and K.Schipper.(2005)The market pricing of accruals quality.Journal of Accounting & Economics 39: 295-327.Francis, J., Nanda, D., and P.Olsson.(2008)Voluntary disclosure, information quality, and costs of capital.Journal of Accounting Research 46(1): 53-99.Gebhardt,W., C.Lee and B.Swaminathan(2001)Towards an ex ante cost of capital.Journal of Accounting Research 39(1): 135-176.Goh, B-W., J.Lee, C-Y.Lim and T.Shevlin(2013)The effect of corporate tax avoidance on the cost of equity.Working paper, Singapore Management University.Gow, I., G.Ormazabal and D.Taylor(2010)Correcting for cross-sectional and time-series dependence in accounting research The Accounting Review 85(2): 483-512.Gray, P., P.Koh and Y.Tong(2009)Accruals quality, information risk and cost of capital: Evidence from Australia.Journal of Business Finance and Accounting 36(1-2): 51-72.Guay, W., S.P.Kothari and S.Shu(2011)Properties of implied cost of capital using analysts’ forecasts.Australian Journal of Management 36(2): 125-149.Hail, L.(2002)The impact of voluntary corporate disclosure on the ex-ante cost of capital for Swiss firms European Accounting Review 11: 741-773.Hail, L., and C.Leuz.(2006)International differences in the cost of equity capital: Do legal institutions and securities regulation matter? Journal of Accounting Research 44(3): 485-531.Healy, P., and K.Palepu(2001)Information asymmetry, corporate disclosure, and the capital markets: A review of the empirical disclosure literature.Journal of Accounting and Economics 31: 405-440.Hirshleifer, D., K.Hou, and S.H.Teoh(2012)The accrual anomaly: Risk or mispricing? Management Science(58-2);320–335.Holthausen, R., and R.Watts(2001)The relevance of value-relevance literature for financial accounting standard setting.Journal of Accounting and Economics(Sept): 3-75.Hribar, P.and T, Jenkins.(2004)The effect of accounting restatements on earnings revisions and the estimated cost of capital.Review of Accounting Studies 9(2-3): 337-356.Hughes, J.S., J.Liu, and J.Liu.(2007)Information asymmetry, diversification, and cost of capital.The Accounting Review 82: 705–729.Hughes, J.S., J.Liu, and J.Liu.(2009)On the association between expected returns and implied cost of capital‖ Review of Accounting Studies 14: 246-259.Hutchens, M.and S.Rego(2013)Tax risk and the cost of equity capital.Working paper, Indiana University.Hwang, L-S., W-J.Lee, S-Y.Lim and K-H.Park,(2013)Does information risk affect the implied cost of equity capital? An analysis of PIN and adjusted PIN.Journal of Accounting and Economics 55(2-3): 148-167.Kim, D., and Y.Qi(2010)Accruals quality, stock returns, and macroeconomic conditions.The Accounting Review 85(3): 937-978.Klein, R., and V.Bawa.(1977)The effect of estimation risk on optimal portfolio choice.Journal of Financial Economics 3: 215–231.Kothari, S.P., X.Li and J.Short.(2009)The effect of disclosures by management, analysts, and financial press on cost of capital, return volatility, and analyst forecasts: A study using content analysis.The Accounting Review 82(5): 1255-1297.Kravet, T.and T.Shevlin.(2010)Accounting restatements and information risk.Review of Accounting Studies 15: 264-294.Kyle, A.(1985)Continuous auctions and insider trade.Econometrica 53(6): 1315-1335.Lambert, R., C.Leuz, and R.Verrecchia.(2007)Accounting information, disclosure, and the cost of capital.Journal of Accounting Research 45(2): 385–420.Lambert, R., C.Leuz, and R.Verrecchia.(2012)Information asymmetry, information precision, and the cost of capital.Review of Finance 16: 1-29.Lambert, R.,(2009)Discussion of ―on the association between expected returns and implied cost of capital‖ Review of Accounting Studies 14: 260-268.Leuz, C., and R.Verrecchia(2004)Firms’ capital allocation choices, information quality, and the cost of capital.Working paper, University of Pennsylvania.Li, V., T.Shevlin and D.Shores(2013)Revisiting the AQ measure of accrual quality.Working paper, University of Washington.Lys, T., and S.Sohn.(1990)The association between revisions of financial analyst’ earnings forecasts and security price changes.Journal of Accounting and Economics 13: 341-363.Mashruwala, C.and S.Mashruwala(2011)The pricing of accrual quality: January versus the rest of the year.The Accounting Review 86(4): 1349-1381.McInnis, J.(2010)Earnings smoothness, average returns and implied cost of equity capital.The Accounting Review 85(1): 315-341.Mohanram, P., and D.Gode(2013)Removing predictable analyst forecast errors to improve implied cost of equity estimates.Review of Accounting Studies 18: 443-478.Ogneva, M., K.R.Subramanyam, and K.Raghunandan(2007)Internal control weakness and cost of equity: Evidence from SOX Section 404 disclosures.The Accounting Review 82(5):1255-1297.Ogneva, M.,(2012)Accrual quality, realized returns, and expected returns: The importance of controlling for cash flow shocks, The Accounting Review 87(4): 1415-1444.Petersen, M.,(2009)Estimating standard errors in finance data panels: Comparing approaches.Review of Financial Studies 22(1): 435-480.Petkova, R.(2006)Do the Fama-French factors proxy for innovation in predictive variables? Journal of Finance 61: 581-612.Reidl, E., and G.Serafeim(2011)Information risk and fair values: An examination of equity betas.Journal of Accounting Research 49(4): 1083-1122.Strobl, G.,(2013)Earnings manipulation and the cost of capital.Journal of Accounting Research, forthcoming.Verrecchia, R.(2001)Essays on disclosure.Journal of Accounting and Economics 32: 97-180.Vuolteenaho, T.(2002)What drives firm-level stock returns? The Journal of Finance 57: 233–264.How Do Various Forms of Auditor Rotation Affect Audit Quality? Evidence from China 内部控制质量、企业风险与权益资本成本——理论分析与实证检验

1.Accruals Quality and Internal Control over Financial Reporting.Accounting Review, Oct2007, Vol.82 Issue5 2.Audit Committee Quality and Internal Control An Empirical Analysis.FullAccounting Review, Apr2005, Vol.80 Issue 2 3.Balancing the Dual Responsibilities of Business Unit Controllers Field and Survey Evidence.Accounting Review, Jul2009, Vol.84 Issue4 4.Corporate Governance and Internal Control over Financial Reporting A Comparison of Regulatory Regimes Accounting Review, May2009, Vol.84 Issue 3 5.Earnings Management of Firms Reporting Material Internal Control Weaknesses under Section 404 of the Sarbanes-Oxley Act.Auditing, Nov2008, Vol.27 Issue 2 6.Economic Incentives for Voluntary Reporting on Internal Risk Management and Control Systems.Auditing, May2008, Vol.27 Issue 6 7.Firm Characteristics and Voluntary Management Reports on Internal Control.Auditing, Nov2006, Vol.25 Issue2 8.Former Audit Partners on the Audit Committee and Internal Control Deficiencies.Accounting Review, Mar2009, Vol.84 9.Internal Control Quality and Audit Pricing under the Sarbanes-Oxley Act.Auditing, May2008, Vol.27 10.Internal Control Weakness and Cost of Equity Evidence from SOX Section 404 Disclosures Accounting Review, Oct2007, Vol.82 11.Internal Control Weaknesses and Information Uncertainty.Accounting Review, May2008, Vol.83 12.Internal Controls and the Detection of Management Fraud.Journal of Accounting Research, Spring99, Vol.37 13.Reducing Management's Influence on Auditors Judgments An Experimental Investigation of SOX 404 Assessments Accounting Review, Nov2008, Vol.83 14.SOX Section 404 Material Weakness Disclosures and Audit Fees.Full Auditing, May2006, Vol.25 15.The Effect of SOX Internal Control Deficiencies and Their Remediation on Accrual Quality.Accounting Review, Jan2008, Vol.83 16.The Impact of SOX Section 404 Internal Control Quality Assessment on Audit Delay in the SOX Era.Auditing, Nov2006, Vol.25

Ashbaugh-Skaife, H., Collins, D.W., & Kinney Jr., W.R.(2007).The discovery and reporting of internal control deficiencies prior to SOX-mandated audits.Journal of Accounting and Economics, 44(1– 2), 166–192.Ashbaugh-Skaife, H., Collins, D.W., Kinney Jr, W.R., & Lafond, R.(2009).The Effect of SOX Internal Control Deficiencies on Firm Risk and Cost of Equity.Journal of Accounting Research, 47(1), 1–43.Bahramian, A.(2011), Evaluation of the effectiveness of internal controls in an Investment Company, Master Thesis in Imam Hossein University, Iran.Daraby, M,(2006), analyzing the effect of strengthening internal controls, audit reports of companies listed on the Stock Audit, Master Thesis in Azan Islamic university.Doyle, J., Ge, W., & McVay, S.(2007).Determinants of weaknesses in internal control over financial reporting.Journal of Accounting and Economics, 44(1–2), 193–223.Feng, M., Li, C., & McVay, S.(2009).Internal control and management guidance.Journal of Accounting and Economics, 48(2–3), 190–209.Maham K., Poriya Nasab, A.(2000), Internal control)Integrated Framework(, Report of the Committee of the Commission Tardy, azman Hesabresy, Pages 118, 135.Ogneva, M., Subramanyam, K.R., & Raghunandan, K.(2007).Internal control weakness and cost of equity: evidence from SOX Section 404 disclosures.The Accounting Review, 82(5), 1255-1297.Rezaie Jahangoshaee, H,(1996).A analytical study of the degree of reliance of independent auditors on firms internal controls, Master Thesis, shahid Beheshti University, Iran.